Explore
Upload

DocSlides is a free service to upload presentations and documents.

Upload Now

Search Results for 'Rbv Weeks'

Rbv Weeks published presentations and documents on DocSlides.

Treatment of Hepatitis C in patients with

Treatment of Hepatitis C in patients with

  • tatyana-admore
  • 31 Slides

thalassaemia. . Where . are we now?. Telaprevir ....

Advances in Hepatitis C Identification and Treatment

Advances in Hepatitis C Identification and Treatment

  • giovanna-bartolotta
  • 67 Slides

Developed by Camilla S. Graham, MD, BIDMC, 5/5/15...

Update on the HCV Antiviral Pipeline

Update on the HCV Antiviral Pipeline

  • natalia-silvester
  • 14 Slides

Todd S. Wills, MD. SPNS HCV Treatment Expansion I...

TURQUOISE-I:

TURQUOISE-I:

  • tawny-fly
  • 18 Slides

SAFETY AND EFFICACY OF ABT-450/R/OMBITASVIR, DASA...

CURRY

CURRY

  • faustina-dinatale
  • 13 Slides

Design. Open-label. CURRY . Study. : SOF + RBV fo...

Daclatasvir in Combination With Sofosbuvir

Daclatasvir in Combination With Sofosbuvir

  • mitsue-stanley
  • 15 Slides

With Or Without Ribavirin Is Safe and Efficacious...

26/07/2013

26/07/2013

  • alida-meadow
  • 14 Slides

1. Le 29-01-2015. Les anticorps neutralisants ant...

Management of HCV in Co-Infected Patients

Management of HCV in Co-Infected Patients

  • danika-pritchard
  • 22 Slides

Marie-Louise Vachon, MD, . MSc. Division of . Inf...

The Resource Based View of the Firm (RBV)

The Resource Based View of the Firm (RBV)

  • celsa-spraggs
  • 36 Slides

B290. The object of strategic analysis…. Explai...

3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in

3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in

  • conchita-marotz
  • 10 Slides

SAPPHIRE-I. Phase 3. . Treatment. . Naïve. Fel...

OBV/PTV/r

OBV/PTV/r

  • kittie-lecroy
  • 7 Slides

+ DSV + RBV. No randomisation. Open-label. TOPAZ-...

Simeprevir in

Simeprevir in

  • ellena-manuel
  • 14 Slides

Genotype . 1 . (. Viral . Relapsers. ). PROMISE ....

Sofosbuvir in

Sofosbuvir in

  • giovanna-bartolotta
  • 9 Slides

Genotype . 2. . or 3 . FUSION. Trial. Phase . ...

Ombitasvir-Paritaprevir-Ritonavir

Ombitasvir-Paritaprevir-Ritonavir

  • sherrill-nordquist
  • 9 Slides

. and Dasabuvir +/- . RBV in . GT1b. PEARL-II. P...

Are Pan-Genotypic Therapies Ready for Prime Time?

Are Pan-Genotypic Therapies Ready for Prime Time?

  • lois-ondreau
  • 21 Slides

3. Rd. International . HIV/Hepatitis . Coinfecti...

Ombitasvir-Paritaprevir

Ombitasvir-Paritaprevir

  • tatiana-dople
  • 9 Slides

-. Ritonavir . and Dasabuvir . + RBV in . GT1. SA...

No randomisation

No randomisation

  • tatiana-dople
  • 6 Slides

N = 100. W12. W24. Arm B: . compensated cirrhosis...

Daclatasvir in Combination With Sofosbuvir

Daclatasvir in Combination With Sofosbuvir

  • mitsue-stanley
  • 15 Slides

With Or Without Ribavirin Is Safe and Efficacious...

OBV/PTV/r

OBV/PTV/r

  • conchita-marotz
  • 5 Slides

OBV/PTV/r + RBV. Randomisation*. 1 : 1. Open labe...

MK3 + RBV

MK3 + RBV

  • jane-oiler
  • 5 Slides

N = 45. N = 49. W24. W16. MK3. > . 18 years. H...

Placebo + PR

Placebo + PR

  • aaron
  • 6 Slides

W24. DCV + PR. Placebo + PR. Yes. Dore GJ. Gastro...

2013 Asilomar HIV Medical Update

2013 Asilomar HIV Medical Update

  • luanne-stotts
  • 74 Slides

David Spach, MD. Clinical Director, Northwest AET...

Sofosbuvir + Peginterferon + Ribavirin in Genotype 2

Sofosbuvir + Peginterferon + Ribavirin in Genotype 2

  • debby-jeon
  • 10 Slides

. or 3 . LONESTAR-2. Phase 2. Treatment. . Exp...

ALLY-1

ALLY-1

  • stefany-barnette
  • 6 Slides

Design. Objective. SVR. 12. (HCV RNA < 25 IU/...

Sofosbuvir, Ribavirin, GS

Sofosbuvir, Ribavirin, GS

  • min-jolicoeur
  • 7 Slides

-. 0938 in GT 1-4. QUANTUM. Phase . 2b. Treatment...

Not randomised Open-label

Not randomised Open-label

  • cheryl-pisano
  • 0 Slides

18-70 years. HCV genotype 1 or 3. Naïve or failu...

The Resource Based View of the Firm (RBV)

The Resource Based View of the Firm (RBV)

  • alida-meadow
  • 0 Slides

B290. The object of strategic analysis…. Explai...

HIV Pipeline Doravirine 2

HIV Pipeline Doravirine 2

  • giovanna-bartolotta
  • 0 Slides

(MK-1439; DOR). . NNRTI. Merck. Filed with USFDA...

Global Hepatitis C Guidelines 2014: recommendations for a public health approach

Global Hepatitis C Guidelines 2014: recommendations for a public health approach

  • olivia-moreira
  • 0 Slides

Gottfried . Hirnschall. Background . HCV infectio...

Resistance to Direct Acting Antiviral Therapy

Resistance to Direct Acting Antiviral Therapy

  • tawny-fly
  • 0 Slides

Resistance to HCV DAAs: What is the threat level...

Community Pharmacy Considerations for HIV

Community Pharmacy Considerations for HIV

  • tawny-fly
  • 0 Slides

& HCV . Therapy. Larry Pineda, . PharmD. , . ...

HIV Pipeline Cabotegravir-LA

HIV Pipeline Cabotegravir-LA

  • liane-varnes
  • 0 Slides

(GSK-744; CAB). For . PrEP. INI. ViiV. Topical mi...

SOF/VEL 400/100 mg qd N = 75

SOF/VEL 400/100 mg qd N = 75

  • danika-pritchard
  • 0 Slides

W24. SOF/VEL. >. 18 years. Chronic HCV infect...

Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir

Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir

  • vamput
  • 59 Slides

Prepared by: . Sophie . Woolston. , MD and David H...

Use of HCV DAAs with HIV Regimens

Use of HCV DAAs with HIV Regimens

  • robaut
  • 13 Slides

Sam Lam, . PharmD. Annie Vong, . PharmD. 2/3/2017....

HIV-HCV Coinfection in the era of effective antiviral therapy

HIV-HCV Coinfection in the era of effective antiviral therapy

  • mia
  • 21 Slides

Mark Sulkowski, . MD. Professor of Medicine. Medic...

Clinical Group

Clinical Group

  • summer
  • 3 Slides

CC By 010 Therapeutic Challenges College of Pharma...

Treatment of Chronic Hepatitis C Virus Infection in Adults

Treatment of Chronic Hepatitis C Virus Infection in Adults

  • tracy
  • 28 Slides

www.hivguidelines.org. APRIL 2023. NYSDOH AIDS Ins...

Hepatitis C in PWIDS London:

Hepatitis C in PWIDS London:

  • obrien
  • 135 Slides

PARTNERSHIP TOWARDS ELIMINATION OF A MAJOR PUBLIC ...

TURQUOISE-I: SAFETY AND EFFICACY OF ABT-450/R/OMBITASVIR, DASABUVIR, AND RIBAVIRIN IN PATIENTS CO-I

TURQUOISE-I: SAFETY AND EFFICACY OF ABT-450/R/OMBITASVIR, DASABUVIR, AND RIBAVIRIN IN PATIENTS CO-I

  • eloise
  • 18 Slides

20. th. International AIDS Conference. • . Melb...

Copyright © 2024 DocSlides. All Rights Reserved